HIGHLIGHTS
- who: ST and collaborators from the Administration, United States Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham have published the article: ST6Gal1: Oncogenic signaling pathways and targets, in the Journal: (JOURNAL)
SUMMARY
Since abnormal glycosylation in malignancy was first described in 1969, it has been established to affect cancer hallmarks (Meezan et_al, 1969; Pinho and Reis, 2015; Munkley and Elliott, 2016; Vajaria and Patel, 2017). Interestingly, a large proportion of cancer biomarkers approved by the FDA are glycosylated proteins, further suggesting the importance of glycobiology in cancer (Moss et_al . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.